Research
Driven by patient needs
Patient-centric innovation is the foundation of Therapeutics Discovery. Every project is inspired by unmet clinical needs, ensuring that the therapies are developed using insights from real patient cases to guide therapeutic design for meaningful clinical impact. This is possible through our translational platform, which focuses on overcoming obstacles in oncology drug development. It aims to accelerate the translation of new discoveries into therapies that benefit patients. Our translational platform collaborates with UT MD Anderson’s clinics to identify novel treatment approaches and conduct clinical trials, demonstrating a commitment to addressing unmet patient needs.
Development across drug classes
Our division works across a wide spectrum of therapeutic modalities, including:
- small-molecule drugs for targeted cancer inhibition
- proximity-based therapeutics
- peptide- and antibody-based radiopharmaceuticals using diverse radionuclides
- protein therapeutics such as: next-generation bispecifics, T-cell receptor conjugates, CAR’s and antibody-drug conjugates.
This broad scope allows us to tailor treatments to different cancer types and patient profiles, maximizing impact.
Our Strengths
Institutional Integration
Therapeutics Discovery operates as a biotech-like engine within UT MD Anderson, leveraging the institution’s vast clinical expertise, research infrastructure and patient access. Seamless collaboration between clinicians, researchers and data scientists accelerates the translation of discoveries into trials and ultimately into practice.
Data Science
Our division uses advanced computational biology, genomics and AI-driven analytics to identify novel drug targets, predict therapeutic responses and optimize compound design. We embrace digital platforms for drug modeling, virtual screening and remote collaboration. These tools allow for rapid iteration, simulation of molecular interactions, and efficient resource allocation, especially critical in early-stage discovery. Our data-rich approach helps reduce failure rates and shortens the time from discovery to clinical testing.
Virtual R&D
We offer our collaborators unprecedented access to rich datasets, biological samples, predictive models and advanced platforms, all designed to accelerate innovation across the research and clinical spectrum. Our dedicated team brings deep expertise from both industry and academia, enabling comprehensive translational capabilities that bridge discovery and application. Through integrated collaboration, we provide representation across the full continuum of drug development, including basic science, translational research, regulatory strategy and clinical science, ensuring seamless progression from concept to clinical impact. Our clinical engine drives rapid translation from bench to bedside and back, supported by access to diverse patient populations that enhance the relevance and reach of our research outcomes.
Novel Clinical Trial Design
Discoveries made by our team enable advancement of therapies into adaptive and biomarker-driven trials, which match therapies to patients based on molecular profiles and allow for real-time adjustments to trial protocols. This approach increases trial efficiency and improves the likelihood of meaningful outcomes for patients.
Strategic Collaborations
Our team works with biopharma companies, academic institutions and biotech startups to co-develop therapies. These strategic collaborations bring together complementary expertise and accelerate innovation.
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.